Cargando…
Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?
Background: The past two decades have witnessed significant growth in non-commercial research and development (R&D) initiatives, particularly for neglected diseases, but there is limited understanding of the ways in which they compare with commercial R&D. This study analyses costs, timelines...
Autores principales: | Vieira, Marcela, Kimmitt, Ryan, Moon, Suerie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063537/ https://www.ncbi.nlm.nih.gov/pubmed/33953909 http://dx.doi.org/10.12688/f1000research.28281.2 |
Ejemplares similares
-
Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System?
por: Moon, Suerie, et al.
Publicado: (2012) -
Rising pharmaceutical innovation in the Global South: a landscape study
por: Vieira, Marcela, et al.
Publicado: (2023) -
What Do Changes in Brain Perfusion Induced by Etomidate Suggest about Epilepsy in Human Patients?
por: Herrera-Peco, Ivan, et al.
Publicado: (2010) -
What do we know about managing Dupuytren’s disease cost-effectively?
por: Dritsaki, Melina, et al.
Publicado: (2018) -
Prevention in practice: why is it neglected and what can we do?
por: Aveyard, Paul, et al.
Publicado: (2022)